Stimulatory Effect of Insulin-like Growth Factor-1 on Renal Pi Transport and Plasma 1,25-dihydroxyvitamin D3
Overview
Authors
Affiliations
Administration of GH increases both the tubular reabsorption of inorganic phosphate (Pi) and the plasma level of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. These two effects could be induced by a common mediator, possibly the GH-generated insulin-like growth factor 1 (IGF-1). In the present work, the influence of recombinant human IGF-1 on renal Pi transport and plasma 1,25-(OH)2D3 was examined in hypophysectomized (HPX) rats. IGF-1, infused by miniosmotic pump at the dose of 10 micrograms/h for 6 days, significantly increased the maximal tubular reabsorption of Pi per unit volume of glomerular filtrate (max TRPi/m1GFR): IGF-1 3.50 +/- 0.16; vehicle: 2.78 +/- 0.14 mumol/m1GFR, P less than 0.005. The response was associated with a marked stimulation of plasma 1,25-(OH)2D3 (IGF-1; 409 +/- 23; vehicle: 208 +/- 22 pmol/liter, P less than 0.001). As previously reported for GH, IGF-1 also increased GFR and reduced urinary sodium excretion. In brush border membrane vesicles isolated from renal cortex of HPX rats, the Na-dependent Pi transport was stimulated by IGF-1. Neither the Na-dependent glucose transport nor that of alanine was affected by the growth factor. The stimulatory effect of IGF-1 on maxTRPi/m1GFR was also expressed in thyroparathyroidectomized (TPTX) HPX rats (IGF-1: 5.20 +/- 0.29; vehicle: 3.88 +/- 0.37 mumol/m1GFR, P less than 0.025). In conclusion, administration of IGF-1 in HPX rats mimics the stimulatory effects of GH on maxTRPi/m1GFR and on plasma 1,25-(OH)2D3. As described for GH the change in maxTRPi/m1GFR is mediated by a PTH independent mechanism and is expressed at the level of the luminal membrane of proximal tubules. These results suggest that IGF-1 could be an important factor in the control of Pi metabolism, particularly during growth, and might play a significant role in mediating the effect of GH on the renal handling of Pi and production of 1,25-(OH)2D3.
Dreyling C, Hasselmann M PLoS One. 2022; 17(6):e0270550.
PMID: 35749523 PMC: 9231785. DOI: 10.1371/journal.pone.0270550.
Dreimane D, Chen A, Bergwitz C Ther Adv Musculoskelet Dis. 2020; 12:1759720X20912862.
PMID: 32963591 PMC: 7488884. DOI: 10.1177/1759720X20912862.
Hyperphosphatemia Management in Patients with Chronic Kidney Disease.
Shaman A, Kowalski S Saudi Pharm J. 2016; 24(4):494-505.
PMID: 27330380 PMC: 4908098. DOI: 10.1016/j.jsps.2015.01.009.
Regulation of serum phosphate.
Lederer E J Physiol. 2014; 592(18):3985-95.
PMID: 24973411 PMC: 4198009. DOI: 10.1113/jphysiol.2014.273979.
Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.
Uebelhart B, Herrmann F, Rizzoli R Clin Cases Miner Bone Metab. 2012; 6(2):163-8.
PMID: 22461168 PMC: 2781229.